Zobrazeno 1 - 10
of 12
pro vyhledávání: '"59"'
Autor:
Isabelle Ruel, Zubin Lahijanian, Daniel Gaudet, Alexandre M. Bélanger, Jacques Genest, Jean Bergeron, Alexis Baass, Etienne Khoury, Latifah Alothman, Diane Brisson, Patrick Couture, Sumayah Aljenedil, Leslie Brown
Publikováno v:
Atherosclerosis. 310:54-63
Background and aims Homozygous familial hypercholesterolemia (HoFH) is an orphan disease, most often caused by bi-allelic mutations of the LDLR gene. Patients with HoFH have elevated LDL-C levels >13 mmol/L, tendinous xanthomata and severe, premature
Publikováno v:
Zaccardi, F, Kunutsor, S K, Seidu, S, Davies, M J & Khunti, K 2018, ' Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction? A network meta-analysis and meta-regression of randomised controlled trials ', Atherosclerosis, vol. 271, pp. 223-231 . https://doi.org/10.1016/j.atherosclerosis.2018.02.035
Background and aims Meta-analyses of randomised controlled trials (RCTs) have suggested a possible benefit of statin treatment on the risk of venous thromboembolism (VTE), with potential differences by type and dose of statins. We aimed to assess dif
Publikováno v:
Atherosclerosis. 130:179-182
Hemodynamic changes associated with the lowering of total cholesterol (TC) by the water-soluble HMG-COA reductase inhibitor pravastatin were investigated in 59 patients with hypercholesterolemia (TC level at least 220 mg/dl) who received pravastatin
Autor:
Akira Yashiro, Akio Kuroiwa, Hiromi Tasaki, Yasuhide Nakashima, Tsuyoshi Toyokawa, Seiya Tanaka, Kazuhito Yamashita
Publikováno v:
Atherosclerosis. 127:43-47
In this study, plasma NO2- and NO3- (NOx-) levels were studied after lowering cholesterol with simvastatin in 26 outpatients with hypercholesterolemia (male, 9; female, 17; mean age, 59 +/- 12 years; cholesterol level220 mg/dl). Simvastatin (5 mg) wa
Autor:
Kiyoshi Hibi, Tetsu Yamaguchi, Masunori Matsuzaki, Takeshi Morimoto, Katsumi Miyauchi, Takeshi Kimura, Satoshi Saito, Hiroyuki Daida, Yukio Ozaki, Kazuo Kimura, Takafumi Hiro, Yoshihisa Nakagawa, Masakazu Yamagishi
Publikováno v:
Atherosclerosis. 219(2)
Aim To clarify whether the effects of statin treatment on plaque regression vary according to the presence or absence of polyvascular disease (PVD) in patients with acute coronary syndrome (ACS). Methods 307 patients with ACS who underwent percutaneo
Publikováno v:
Atherosclerosis. 93:217-228
Leukocyte adhesion and other injury parameters have been studied in the aortic endothelium of Sprague-Dawley rats in two situations: (1) spontaneous pathology in conventional rats with antibodies to Mycoplasma pulmonis and/or Kilham or Sendai viruses
Autor:
Krzysztof Labuzek, Robert Krysiak, A Madej, Bogusław Okopień, Zbigniew S. Herman, Belowski D, Jan Kowalski, Marek Zieliński
Publikováno v:
Atherosclerosis. 176(2)
The aim of the study was to assess the effect of two major groups of hypolipemic drugs, HMG-CoA reductase inhibitors (statins) and PPARα activators (fibrates), on the secretory function of T-lymphocytes in patients with primary type II dyslipidemia.
Publikováno v:
Atherosclerosis. 104(1-2)
Recent studies demonstrated that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase lower plasma triglyceride primarily by decreasing hepatic secretion of very low density lipoproteins (VLDL). A possible mechanism is that inhibit
Publikováno v:
Atherosclerosis. 53:91-98
The effects of the calcium antagonist, nifedipine, on atherogenesis were investigated in WHHL rabbits, a unique animal model for human familial hypercholesterolemia. Nifedipine, in a daily dose of 40 mg, was fed orally to 9 rabbits over a period of 2
Autor:
Lars A. Carlson, Gunnar Rosenhamer
Publikováno v:
Atherosclerosis. 37:129-138
Over a three and a half year period beginning in December 1972, 555 survivors of myocardial infarction (442 men and 113 women) under the age of 70 years were recruited from one hospital for a therapeutic trial aimed to reduce serum lipids and to stud